ARTICLE | Clinical News
ALKS 8700: Ph III started
March 17, 2017 1:00 PM UTC
Alkermes began a double-blind Phase III trial to compare 462 mg oral ALKS 8700 twice daily for 5 weeks vs. 240 mg oral Tecfidera dimethyl fumarate twice daily in about 420 patients. The study is part ...
BCIQ Company Profiles